Heterozygous pathogenic GVs in BRCA2 are associated with HRR deficiency and susceptibility to female breast, male breast, esophageal, gastric, pancreatic, ovarian, and prostate cancer [41, 55]. This evidence concerns the gene BRCA2 and prostate carcinoma.